132 related articles for article (PubMed ID: 31499745)
1. Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature review.
Hou GX; Song BB
Math Biosci Eng; 2019 Jun; 16(5):5923-5930. PubMed ID: 31499745
[TBL] [Abstract][Full Text] [Related]
2. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment with trastuzumab and crizotinib in metastatic gastric cancer harboring Her-2 amplification and c-MET amplification: A case report.
Liu M
Medicine (Baltimore); 2021 Sep; 100(36):e27017. PubMed ID: 34516491
[TBL] [Abstract][Full Text] [Related]
4. MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer.
Yang Y; Wu N; Shen J; Teixido C; Sun X; Lin Z; Qian X; Zou Z; Guan W; Yu L; Rosell R; Liu B; Wei J
Gastric Cancer; 2016 Jul; 19(3):778-88. PubMed ID: 26404902
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib-resistant
Shen B; Wu F; Ye J; Liang R; Wang R; Yu R; Wu X; Shao YW; Feng J
Future Oncol; 2019 Aug; 15(22):2585-2593. PubMed ID: 31339066
[No Abstract] [Full Text] [Related]
6. De Novo MET Amplification in Chinese Patients With Non-Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study.
Song Z; Wang H; Yu Z; Lu P; Xu C; Chen G; Zhang Y
Clin Lung Cancer; 2019 Mar; 20(2):e171-e176. PubMed ID: 30554986
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
Du J; Wu X; Tong X; Wang X; Wei J; Yang Y; Chang Z; Mao Y; Shao YW; Liu B
Oncotarget; 2017 Apr; 8(16):26281-26287. PubMed ID: 28460431
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
9. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
Rabeau A; Rouquette I; Vantelon JM; Taranchon-Clermont E; Mazières J
Rev Mal Respir; 2017 Jan; 34(1):57-60. PubMed ID: 27745897
[TBL] [Abstract][Full Text] [Related]
10. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
[TBL] [Abstract][Full Text] [Related]
11. Treatment of a pediatric patient with MET-amplified signet ring cell adenocarcinoma of the stomach with crizotinib.
Sabree S; Berg D; Sato M
Pediatr Blood Cancer; 2018 Jun; 65(6):e26984. PubMed ID: 29380521
[No Abstract] [Full Text] [Related]
12. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
[TBL] [Abstract][Full Text] [Related]
13. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer.
Mizutani T; Onda M; Tokunaga A; Yamanaka N; Sugisaki Y
Cancer; 1993 Oct; 72(7):2083-8. PubMed ID: 8397058
[TBL] [Abstract][Full Text] [Related]
14. Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
Riedel R; Michels S; Heydt C; Siemanowski J; Kobe C; Bunck A; Schäfer S; Fischer RN; Scheffler M; Abdulla DSY; Nogová L; Koleczko S; Merkelbach-Bruse S; Büttner R; Wolf J
Lung Cancer; 2019 Jul; 133():20-22. PubMed ID: 31200822
[TBL] [Abstract][Full Text] [Related]
15. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.
Kim HS; Chon HJ; Kim H; Shin SJ; Wacheck V; Gruver AM; Kim JS; Rha SY; Chung HC
J Surg Oncol; 2018 Jun; 117(8):1679-1686. PubMed ID: 29790169
[TBL] [Abstract][Full Text] [Related]
16. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.
An X; Wang F; Shao Q; Wang FH; Wang ZQ; Wang ZQ; Chen C; Li C; Luo HY; Zhang DS; Xu RH; Li YH
Cancer; 2014 Mar; 120(5):675-82. PubMed ID: 24804300
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient.
Zhou S; Xu B; Qi L; Zhu D; Liu B; Wei J
Cancer Biol Ther; 2019; 20(1):15-20. PubMed ID: 30118648
[TBL] [Abstract][Full Text] [Related]
18. The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program.
Aparicio T; Cozic N; de la Fouchardière C; Meriaux E; Plaza J; Mineur L; Guimbaud R; Samalin E; Mary F; Lecomte T; Gomez-Roca C; Haineaux PA; Gratet A; Selves J; Menu Y; Colignon N; Johnson L; Legrand F; Vassal G
Target Oncol; 2021 May; 16(3):381-388. PubMed ID: 33847874
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.
Li YQ; Song SS; Jiang SH; Zhang XY
Ann Oncol; 2017 Oct; 28(10):2622-2624. PubMed ID: 28961830
[No Abstract] [Full Text] [Related]
20. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
